djuvant chemotherapy for breast cancer has undergone a major change over the past two decades. Chemotherapy with a regimen that includes an anthracycline or a combination of cyclophosphamide, methotrexate, and fluorouracil significantly decreases the risks of disease recurrence and death among women with earlystage breast cancer. 1 The overview analysis of the Early Breast Cancer Trialists' Collaborative Group demonstrated that, as compared with standard treatment with cyclophosphamide, methotrexate, and fluorouracil, regimens that contained doxorubicin or epirubicin reduced the annual risk of recurrence of breast cancer by 12 percent and the annual risk of death by 11 percent. Rates of disease-free and overall survival were similar among women treated with either six cycles (spanning 24 weeks) of cyclophosphamide, methotrexate, and fluorouracil or four cycles (12 weeks) of doxorubicin plus cyclophosphamide. 2 Six cycles of fluorouracil, doxorubicin, and cyclophosphamide (FAC), given in various doses and according to various schedules, or fluorouracil, epirubicin, and cyclophosphamide appear superior to six cycles of cyclophosphamide, methotrexate, and fluorouracil in early-stage breast cancer, 1,3,4 and six cycles of adjuvant fluorouracil, epirubicin, and cyclophosphamide are better than three cycles in terms of disease-free and overall survival. 5 Therefore, at the time this trial was initiated, six cycles of FAC; cyclophosphamide, doxorubicin, and fluorouracil; or fluorouracil, epirubicin, and cyclophosphamide every three weeks were generally accepted as appropriate adjuvant regimens for the treatment of early breast cancer. 6 Although various regimens with fluorouracil, doxorubicin, and cyclophosphamide that differed in schedule and dose were developed, [7] [8] [9] [10] no randomized, prospective, comparative trial has demonstrated the superiority of any one regimen.
Docetaxel, an active agent in the treatment of breast cancer, 11 is not cross-resistant with anthracyclines, 12, 13 appears to be more active than doxorubicin, 14 and does not interfere with the pharmacokinetics of doxorubicin, 15, 16 indicating that, unlike paclitaxel, [17] [18] [19] it may not exacerbate doxorubicinrelated cardiotoxicity. 20, 21 Three large randomized trials involving treatments for metastatic breast cancer found that regimens of docetaxel plus doxorubicin and of docetaxel, doxorubicin, and cyclophosphamide (TAC) have antitumor activity superior to that of doxorubicin plus cyclophosphamide and that of FAC, although survival was not significantly different between the treatment groups in two of the three studies. [21] [22] [23] In 1997, the Breast Cancer International Research Group began a phase 3 trial to compare the docetaxel-containing regimen TAC with a regimen of FAC as adjuvant treatment for women with operable node-positive breast cancer. At a planned interim analysis at 33 months (August 2001), we reported a statistically significant improvement in the rate of disease-free survival among patients treated with TAC as compared with those treated with FAC (hazard ratio, 0.68; P=0.0011). 24 Because the results of this analysis did not meet the predefined P value of less than 0.001 to ascertain a statistically significant difference between TAC and FAC, 25 the independent data monitoring committee recommended that the protocol be amended to include a second interim analysis, to be conducted at the point at which there had been 400 events, in addition to the protocolspecified final analysis after 590 disease-free survival events. The comparison was to be performed at the level of P=0.001 for the primary end point of disease-free survival. We report the results of the second interim analysis, which was performed after a median follow-up period of 55 months (after 399 disease-free survival events).
study population
Women eligible for the study were between 18 and 70 years of age, had a score on the Karnofsky performance scale of 80 percent or more, and had undergone primary surgery (i.e., mastectomy, tumorectomy, or lumpectomy) with axillary-node dissection (sentinel-node biopsy was not routine practice) for unilateral, operable carcinoma of the breast. Patients were randomly assigned to a study group within 60 days after surgery. All patients had at least one axillary lymph node that was positive for cancer on histologic examination. The margins of resected specimens had to be histologically free of invasive adenocarcinoma and ductal carcinoma in situ. A complete staging workup within three months before registration -including bilateral mammography; chest radiography; abdominal ultrasonography, computed tomography, or both; and bone scanning -and an assessment of the left ventricular ejection fraction with the use of multiple gated acquisition scanning or echocardiography were mandatory.
Criteria for exclusion included advanced disease (i.e., T4, N2 or N3, or M1), a history of other cancers, motor or sensory neuropathy of grade 2 or more according to the National Cancer Institute Common Toxicity Criteria, pregnancy, lactation, and any serious illness or medical condition other than breast cancer. Prior therapy with anthracyclines or taxanes was not allowed.
The study was approved by the ethics committees or institutional review boards of all participating institutions. All patients provided written informed consent. The trial was conducted according to Good Clinical Practice and International Conference on Harmonization rules, including verification of source data.
study design
In this phase 3, multicenter, prospective trial, randomization was stratified according to institution and number of involved axillary lymph nodes per patient (one to three vs. four or more). On day 1 of each of six 21-day cycles, eligible patients received either TAC (50 mg of doxorubicin per square meter of body-surface area in an intravenous infusion for 15 minutes, followed by 500 mg of cyclophosphamide per square meter administered intravenously for 1 to 5 minutes and then, after a 1-hour interval, 75 mg of docetaxel per square meter in an intravenous infusion for 1 hour) or FAC (50 mg of doxorubicin per square meter followed by 500 mg of fluorouracil per square meter, each as an intravenous infusion for 15 minutes, and then 500 mg of cyclophosphamide per square meter in an intravenous infusion for 1 to 5 minutes).
The primary end point was disease-free survival, defined as the time from randomization to the date of a clinical relapse (with histopathologic confirmation or radiologic evidence of tumor recurrence), a second cancer (with the exception of skin cancer other than melanoma, ductal or lobular carcinoma in situ of the breast, or in situ carcinoma of the cervix), or death, whichever occurred first. Secondary end points included overall survival (i.e., the time from randomization until death from any cause), toxic effects, and quality of life.
study procedures

Concomitant Therapy and Dose Modifications
Patients randomly assigned to receive TAC received dexamethasone premedication (8 mg orally every 12 hours six times beginning the day before treatment started) to prevent docetaxel-related hypersensitivity and fluid retention. All patients were to receive a prophylactic antibiotic (500 mg of ciprofloxacin twice daily on days 5 to 14 of each cycle). Patients in the FAC group received prophylactic antibiotics only after an episode of febrile neutropenia or infection. Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was not permitted. However, among patients who had one episode of febrile neutropenia or infection in subsequent cycles, administration of G-CSF was mandatory (150 µg of lenograstim per square meter per day or 5 µg of filgrastim per kilogram of body weight per day on days 4 to 11).
On completion of chemotherapy, tamoxifen (20 mg daily for five years) was administered to patients with estrogen-receptor-positive tumors, progesterone-receptor-positive tumors, or both. Radiotherapy was mandatory after breast-conserving surgery and was administered after mastectomy according to each institution's guidelines.
Dose modifications were planned according to standard toxicity criteria. Discontinuation of treatment was required for patients in whom there were nonhematologic grade 4 toxic effects according to the National Cancer Institute Common Toxicity Criteria, grade 3 toxic effects despite a dose reduction, or clinically significant cardiac events.
Evaluations
Blood counts and general biochemical and clinical assessments, including those for toxic effects, were performed on day 21 of each cycle and then every six months for the first five years of follow-up, after which they were performed annually. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria version 1.0. Chest radiography was repeated every 12 months for the first 5 years of follow-up. Mammography was repeated annually during follow-up.
Estrogen-receptor and progesterone-receptor status in the tumor was evaluated by immunohistochemical analysis. 26 HER2/neu gene amplification was evaluated by fluorescence in situ hybridization, with a positive result defined as a ratio of HER2/neu to chromosome 17 of greater than 2.0. [27] [28] [29] [30] Assessments of hormone receptors and HER2/neu status were performed at the Cross Cancer Institute in Edmonton, Alberta, Canada.
of Cancer Quality of Life Questionnaire (QLQ-C30, version 2.0) and the breast-cancer-specific QLQ-BR23 (version 1.0). The QLQ-C30 includes nine multiple-item scales pertaining to symptoms, five to function, and one to overall health -the global health status and quality-of-life scale. The QLQ-BR23 includes 23 questions regarding disease symptoms, treatment-related side effects, body image, sexuality, and future perspective. Patients were asked to complete both questionnaires on seven occasions: at baseline; before cycles 3 and 5; 3 to 4 weeks after the last cycle; and 6, 12, and 24 months after the last cycle.
Statistical Analysis
The trial was designed to have an overall power of 97 percent to detect a 27 percent reduction in the risk of relapse among patients treated with TAC as compared with those treated with FAC, regardless of nodal status. In addition, the study had 90 percent power to detect a 33 percent reduction in the risk of death. At the final analysis (i.e., at the point at which there were 590 patients), the sample size of 1491 patients would allow the detection, with 90 percent power, of a 27 percent reduction in the risk of relapse in favor of treatment with TAC among patients who had one to three positive lymph nodes. For the subgroup of patients with four or more positive nodes, the sample size would provide 80 percent power to detect a 29 percent reduction in the risk of relapse in favor of treatment with TAC.
The primary analysis was conducted according to the intention-to-treat principle, and a stratified log-rank test was used to compare TAC with FAC with respect to both disease-free and overall survival. The number of positive nodes (one to three or four or more) was the only stratification variable in the analysis. Analyses of subgroups according to hormone-receptor status and HER2/neu status were prospectively defined but were not powered. Unadjusted analyses and analyses according to the Cox proportional-hazards model (adjusted for age, tumor size, nodal status, hormone-receptor status, and HER2/neu status) were performed to estimate disease-free and overall survival. The Kaplan-Meier method was used to calculate probability estimates of disease-free and overall survival. Hypothesis testing was two-sided. Hazard ratios and 95 percent confidence intervals were obtained from the Cox proportional-hazards model. The primary qualityof-life analysis was performed with the use of the scores from the global health status and qualityof-life scale. A repeated-measures mixed-effect analysis of variance was performed to analyze the evolution of the scores on the global health status subscale over time.
The protocol was designed by the study chairs of the Breast Cancer International Research Group in collaboration with Aventis personnel. The data were collected and maintained by the Breast Cancer International Research Group. All analyses were conducted according to the protocol. The efficacy analyses were performed by the independent data monitoring committee; other analyses were conducted by Aventis personnel. Submission of the results for publication was mandated by the independent data monitoring committee. The manuscript was drafted by Dr. Martin and modified after review by the cochairs and other coauthors. A reviewer at Aventis evaluated the manuscript but did not participate in writing it. The final content of the manuscript was determined entirely by the investigators.
patients
Between June 1997 and June 1999, 1491 women from 20 countries were enrolled in the study. Eleven women (1 who had been randomly assigned to receive TAC and 10 assigned to receive FAC) did not receive any treatment, for the following reasons: 8 withdrew consent, 1 was lost to follow-up, and 2 did not receive treatment for other reasons. In total, 1480 patients (744 in the TAC group and 736 in the FAC group) were treated and were included in the safety analysis. Efficacy analyses were based on the intention-to-treat principle (1491 patients) and on populations of patients who were eligible according to the protocol (1421 patients). Seventy patients (4.7 percent of all those enrolled) -36 in the TAC group and 34 in the FAC group -were ineligible. The most common reason for ineligibility in both groups was indeterminate hormone-receptor status at randomization (21 women in the TAC group and 19 in the FAC group). The groups were well balanced in terms of demographic and tumor characteristics (Table 1) . was modified (by a delay, a dose reduction, or both) for 250 patients in the TAC group (33.6 percent) and 293 in the FAC group (39.8 percent). The most frequent reason for delaying a cycle of treatment was the occurrence of hematologic toxic effects. Adjuvant radiotherapy 31 was administered to 68.8 percent of the patients in the TAC group and 71.9 percent of those in the FAC group. Among women with hormone-receptor-positive tumors, the rates of compliance with tamoxifen treatment, as planned according to the protocol, were 94.9 percent in the TAC group and 93.7 percent in the FAC group.
efficacy
The efficacy analysis was performed after it had been documented that 399 events had been recorded (172 in the TAC group and 227 in the FAC group) as of July 15, 2003 , representing a median follow-up period of 55 months (Table 2) . Ninety-seven per-* TAC denotes docetaxel plus doxorubicin and cyclophosphamide, and FAC fluorouracil plus doxorubicin and cyclophosphamide. † Premenopausal women were those in whom the last menses had occurred within the previous six months and who had not previously had bilateral ovariectomy or estrogen-replacement therapy (including women of unknown status less than 50 years of age). ‡ Postmenopausal women were those who had had a prior bilateral ovariectomy or in whom more than 12 months had passed since the last menses, with no prior hysterectomy (including women of unknown status 50 years of age or older). § For the central review, estrogen-receptor status was assessed with clone 6F11; progesterone-receptor status was assessed with clone 636 with the use of tumor blocks or unstained slides. ¶ HER2/neu status was determined by fluorescence in situ hybridization for 1250 patients. Immunohistochemistry with clone CB11 was used for 12 patients. The status of the remaining patients was not assessed owing to a lack of tumor specimens. ¿ Women who had surgery were among the treated patients (744 in the TAC group and 736 in the FAC group). cent of the patients in the study completed at least 45 months of follow-up. The estimated rates of disease-free survival at five years were 75 percent in the TAC group and 68 percent in the FAC group (P=0.001). This difference was due mainly to the greater number of patients in the FAC group who had relapses of breast cancer at distant sites (Table 2) . Similar results were observed in the eligible population as well as in the unadjusted and multivariate analyses (Fig. 1A) . After adjustment for nodal status, treatment with TAC, as compared with FAC, was associated with a 28 percent reduction in the risk of relapse (hazard ratio, 0.72; 95 percent confidence interval, 0.59 to 0.88) (Fig. 1A) .
The superiority of TAC over FAC was also observed in all planned subgroup analyses, which included the number of involved axillary lymph nodes, hormone-receptor status, and HER2/neu status, and was independent of menopausal status (a factor in the sensitivity analysis) (Fig. 2) . In the subgroup of patients with one to three positive nodes, treatment with TAC reduced the risk of relapse by 39 percent (hazard ratio, 0.61; 95 percent confidence interval, 0.46 to 0.82; P<0.001). Among women with four or more positive nodes, treatment with TAC reduced the risk of relapse by 17 percent (hazard ratio, 0.83; 95 percent confidence interval, 0.63 to 1.08; P=0.17). Analysis with the Cox model did not detect any difference in the treatment effect between the two nodal-status strata (ratio of hazard ratios, 1.34; P=0.15), suggesting that TAC was superior to FAC, regardless of the number of lymph nodes involved.
Of the 221 deaths, 91 were in the TAC group and 130 in the FAC group; TAC was associated with a 30 percent lower risk of death than was FAC (hazard ratio, 0.70; 95 percent confidence interval, 0.53 to 0.91; P=0.008) (Fig. 1B) . The estimated overall survival rates at five years were 87 percent in the TAC group and 81 percent in the FAC group.
toxic effects
Overall, the incidence of grade 3 or 4 or severe nonhematologic adverse events, regardless of type, was 36.3 percent in the TAC group and 26.6 percent in the FAC group (P<0.001). The incidence of grade 3 or 4 neutropenia was 65.5 percent in the TAC group and 49.3 percent in the FAC group (P<0.001); febrile neutropenia was observed in 24.7 percent of the patients in the TAC group and 2.5 percent of those in the FAC group (P<0.001) ( Table 3) . Grade 3 or 4 infections occurred in 3.9 percent of patients treated with TAC and 2.2 percent of those treated with FAC (P=0.05); no deaths occurred as a result of infection (Table 4 ). The overall incidence of congestive heart failure (including that during followup) was 1.6 percent among patients treated with TAC and 0.7 percent for those treated with FAC (P=0.09). As of the cutoff date for this analysis, the only secondary hematologic cancer was acute myeloid leukemia, which developed in two patients in the TAC group and one patient in the FAC group.
quality of life
All baseline quality-of-life values were similar between the two treatment groups, with a mean score of 72 (on a scale of 0 to 100, with higher scores representing a better quality of life) in both groups on the global health status subscale of the Quality of Life Questionnaire. The mean scores at the end of treatment were 62 in the TAC group (95 percent confidence interval, 61 to 64) and 69 in the FAC group (95 percent confidence interval, 67 to 70). At the first follow-up visit, the quality-of-life scores either returned to or were higher than those at baseline in both groups, with scores of 76 in the TAC group (95 percent confidence interval, 74 to 77) and 75 in the FAC group (95 percent confidence in-* Events are those included in the analysis of disease-free survival. TAC denotes docetaxel plus doxorubicin and cyclophosphamide, and FAC fluorouracil plus doxorubicin and cyclophosphamide. This randomized, phase 3 trial of adjuvant chemotherapy in women with operable node-positive breast cancer showed that, at a median follow-up of 55 months, the estimated rate of disease-free survival at 5 years was 75 percent in the TAC group and 68 percent in the FAC group (P=0.001). The relative risk of death was 30 percent lower among women in the TAC group than among those in the FAC group. Moreover, treatment with TAC, as compared with FAC, was associated with a 28 percent relative reduction in the risk of relapse. The reduction in the risk of relapse did not seem to be driven by nodal status or by hormone-receptor or HER2/neu status. A final analysis of this trial at 590 events will be required to confirm and extend the findings of the main and subgroup analyses. Although amenorrhea occurred more frequently among women in the TAC group (61.7 percent) than among those in the FAC group (52.4 percent) (P=0.007), the superior efficacy of TAC over FAC in terms of diseasefree survival was independent of menopausal sta- tus. The observation that the benefits of treatment with docetaxel are independent of hormone-receptor status are consistent with the findings of the National Surgical Adjuvant Breast and Bowel Project trial B-27, 32 in which patients with breast cancer who were treated with presurgical doxorubicin plus cyclophosphamide followed by docetaxel had higher rates of complete pathological response than did those treated with doxorubicin plus cyclophosphamide alone, regardless of hormone-receptor status.
The symmetrical design of this trial -in which patients underwent six cycles of treatment with either FAC or TAC, followed by tamoxifen therapy, radiation therapy, or both, as indicated -demonstrates a benefit with the replacement of fluorouracil by docetaxel. Six cycles of three-drug, anthracycline-based regimens are considered among the most effective treatments for node-positive breast cancer. 6 The FAC regimen generally used in North America (two doses of fluorouracil per cycle) was not directly compared with the FAC regimen we selected, and there is no evidence that the omission of a dose of fluorouracil would influence the patients' outcomes. At the dose and schedule used in this trial, FAC is an appropriate control chemotherapeutic regimen. The TAC combination in this trial was also administered at a feasible dose and schedule. In both groups, the dosage of doxorubicin was 50 mg per square meter for six cycles (for a total of 300 mg per square meter).
The Cancer and Leukemia Group B trial 9344 did not demonstrate a benefit with an escalation of the doxorubicin dosage (240, 300, or 360 mg per square meter, delivered over four cycles). 33 Another study of adjuvant therapy 34 showed that administering chemotherapy at shorter intervals (every two weeks vs. every three weeks) significantly improved Premenopausal patients included those whose menopausal status was unknown but who were less than 50 years of age; postmenopausal patients included those whose menopausal status was unknown but who were 50 years of age or older. TAC denotes docetaxel plus doxorubicin and cyclophosphamide, FAC fluorouracil plus doxorubicin and cyclophosphamide, ITT intention to treat, and CI confidence interval. * TAC denotes docetaxel plus doxorubicin and cyclophosphamide, and FAC fluorouracil plus doxorubicin and cyclophosphamide. † P values were calculated with the use of the chi-square test unless otherwise specified. ‡ The study protocol defined febrile neutropenia as fever of grade 2 or more concomitant with grade 4 neutropenia requiring intravenous antibiotics, hospitalization, or both. The National Cancer Institute Common Toxicity Criteria (NCI CTC) definition 2.0 is fever of 38°C or more concomitant with grade 3 or 4 neutropenia. § The study protocol defined neutropenic infection as that of grade 2 or more concomitant with grade 3 or 4 neutropenia. The NCI CTC definition 2.0 is infection of any grade concomitant with grade 3 or 4 neutropenia. ¶ Amenorrhea was defined as the absence of menses for at least three months. Percentages were calculated among premenopausal patients (420 in the TAC group and 403 in the FAC group) who could be evaluated for safety and were treated with study drugs. ¿ P values were calculated according to Fisher's exact test. ** Grade 2 neurosensory effects occurred in 3.6 percent of patients in the TAC group and 1.4 percent in the FAC group. clinical outcomes, raising the possibility that alternative schedules and durations of treatment may further improve outcomes in this setting. A comparison of a dose-dense regimen (treatment administered every two weeks) and the TAC regimen used in the current trial will be part of the National Surgical Adjuvant Breast and Bowel Project trial B-38. The toxic effects associated with the TAC regimen we used are consistent with those reported in association with TAC in women with advanced breast cancer 20, 22 and were manageable with standard supportive measures. Grade 3 or 4 neutropenia was common in both groups (65.5 percent in the TAC group and 49.3 percent in the FAC group, P<0.001). Although the incidence of febrile neutropenia was higher among women treated with TAC (despite the administration of prophylactic ciprofloxacin) than among those treated with FAC (24.7 percent and 2.5 percent), grade 3 or 4 infection was seen in only 3.9 percent of patients in the TAC group, and no deaths due to sepsis occurred. Considering that the rates of febrile neutropenia did not reach the recommended threshold for routine prophylactic administration of G-CSF, 35 the administration of primary prophylaxis with G-CSF should be left to the discretion of the treating physician. However, on the basis of good practice, after an episode of febrile neutropenia, prophylaxis with G-CSF is recommended for all subsequent cycles.
Most patients completed all six treatment cycles (91.3 percent in the TAC group and 96.6 percent in the FAC group), and one third required a delay in or adjustment of treatment (33.6 percent in the TAC group and 39.8 percent in the FAC group). The incidence of congestive heart failure was 1.6 percent among patients treated with TAC, which is consistent with the incidence associated with anthracycline-based adjuvant chemotherapy. 4, 33, 34 The tolerability of adjuvant chemotherapy and the magnitude of deterioration in quality of life are important considerations in a woman's decision to undergo treatment. It is reassuring to note that although both chemotherapy regimens in our trial were associated with transient, statistically significant reductions in quality-of-life scores, these scores returned to baseline levels at the first follow-up visit after treatment and were similar between the treatment groups.
In conclusion, this interim analysis of the Breast Cancer International Research Group trial 001 demonstrates a therapeutic advantage of TAC over FAC, but at the expense of increased toxic effects. Furthermore, chemotherapeutic treatment with TAC led to only a transient reduction in quality-of-life scores, which subsequently returned to pretreatment baseline values.
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